Skip to main content

Day: June 12, 2023

KUKE MUSIC HAS ESTABLISHED A BRAND-NEW OPERATING CENTER IN WUHAN, AIMING TO OPTIMIZE COST EFFICIENCY

Beijing, June 12, 2023 (GLOBE NEWSWIRE) —  Kuke Music Holding Limited (“Kuke” or the “Company”) (NYSE: KUKE), a leading classical music service platform in China with approximately 3 million audio and video music tracks, announced the establishment of a new operating center in Wuhan, the capital city of Hubei Province, China. Kuke Music plans to relocate its marketing and technology departments to the Wuhan operating center. As a significant transportation hub and economic center in China, Wuhan boasts a well-developed transportation network and excellent infrastructure, which will facilitate the company’s connections with various regions across the country. Additionally, Wuhan offers relatively reasonable operating costs, abundant talent resources, and high-quality educational institutions, providing...

Continue reading

Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive Officer Dr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist (now Merck & Co.) for $535 million in 2013LOS ANGELES, June 12, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., has been appointed to the Company’s Board of Directors. Dr. McKinnell brings significant leadership to Nexcella: developing, launching and commercializing drug candidates; building world-class...

Continue reading

ŽEMAITIJOS PIENAS, AB has agreed with bank on the loan of 12 millions 135.2 thousand euros

ŽEMAITIJOS PIENAS, AB (hereinafter – the Company) entered into a business loan transaction with SEB bankas, under which the Company is granted a business loan of 12 millions 135.2 thousand euros.The purpose of the loan is the construction of wind turbines with all secondary items, appurtenances, and/or engineering equipment and facilities in Skurvydiškė Village, Telšiai District Municipality. Arnas MatuzasHead of Legal E-mail: a.matuzas@zpienas.lt 

Continue reading

The sales of „Vilvi Group“ May 2023

“Vilvi Group”, which consists of Vilkyškių pieninė AB, “Modest” AB, Kelmės pieninė AB, “Kelmės pienas” UAB, “Pieno logistika” AB and “Baltic Dairy Board” SIA, consolidated sales for May 2023 amounted to 15.66 million EUR 24% decrease comparing to May 2022. The sales of the Group for period January – May 2023 amounted to 85.48 million EUR 5.6% decrease comparing to the same period last year. Vilija Milaseviciute Economics and finance directorPhone: +370 441 55 102

Continue reading

Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The PK run-in cohort consists of six patients, all of whom will be treated with (Z)-endoxifen at 40mg/day...

Continue reading

New Publication Highlights Basic Science Supporting Simufilam

Publication Reviews Certain Receptor-Protein Interactions.Provides Overview of Basic Science Supporting Simufilam.Published in Drug Development Research, a Peer-Reviewed Journal.AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced a new science publication in Drug Development Research, a peer-reviewed journal. This article reviews certain receptor-protein interactions, including an overview of basic science supporting simufilam. Simufilam is Cassava Sciences’ oral investigational drug candidate that is currently in Phase 3 clinical trials in patients with mild-to-moderate Alzheimer’s disease dementia. “This paper highlights the role of altered filamin A and its receptor interactions in Alzheimer’s...

Continue reading

IR-MED Honors Juneteenth with Commitment to Healthcare Equality: PressureSafe Device Sees Beneath the Skin to Address Inequality in Pressure Injuries

IR-Med, Inc. PressureSafe deviceEarly detection of pressure injuries can be challenging for minority populations due to the current method of visual inspection Patients with dark skin tones suffered more than twice as much as those with lighter skin, evidencing a major health inequality in the U.S. Dr. Dalton, a visionary healthcare thought leader and hall of fame CEO, is supporting IR-Med in analyzing the benefits of the PressureSafe device for African American and Hispanic populations in the U.S.Rosh Pina, Israel, June 12, 2023 (GLOBE NEWSWIRE) — IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address significant healthcare needs, today reiterated its commitment to healthcare equality globally and particularly in the U.S. Pressure...

Continue reading

Amplify ETFs Doubles Product Line with Agreement To Acquire ETF Managers Group’s Exchange-Traded Funds

The transaction covers over $3.5 billion in ETF assets expanding Amplify ETFs’ income, thematic, and core offerings. LISLE, Ill. and SUMMIT, N.J., June 12, 2023 (GLOBE NEWSWIRE) — Amplify ETFs and ETF Managers Group (ETFMG) announced today a definitive agreement under which Amplify ETFs will acquire ETFMG’s exchange-traded funds (ETFs) lineup. In addition to complementing Amplify ETFs’ current suite of income, thematic, and core ETFs, this acquisition will double its offerings and provide investors access to many first-to-market, innovative, and transformational trends through an expanded thematic lineup. “ETFMG has created an impressive roster of strategies and we are excited to acquire its ETFs as these strategies align well with our commitment to being at the forefront of ETF industry growth and innovation,” said Christian...

Continue reading

Interactive Strength Inc. Secures $15M Credit Facility to Support Increased Demand

AUSTIN, TX, June 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Interactive Strength Inc. d/b/a FORME (the “Company”, or “FORME”) (NASDAQ: TRNR), maker of premium smart home gyms and provider of virtual personal training services, announces that on June 6th the Company signed a note purchase agreement to issue senior secured notes (the “Notes”) with gross proceeds to the Company of up to $15.0 million. The lead investor has committed to purchase at least $7.5 million of the Notes and the Notes have a two-year maturity, at 10.0% interest per annum, and with a 5.0% original issuance discount, representing a total cost of debt of 12.5% over the term of the Notes. FORME recently announced partnerships with the luxury hotel chain Aethos and sports retail company SIGNA Sports United. Aethos has hotels and...

Continue reading

HashiCorp 2023 State of Cloud Strategy Survey Shows Cloud Maturity Drives Operational Efficiency

Survey highlights the benefits of reaching cloud maturity, including retaining talent, cost savings, security posture, and operational efficiency SAN FRANCISCO, June 12, 2023 (GLOBE NEWSWIRE) — HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today released its 2023 State of Cloud Strategy Survey, showing positive business outcomes for organizations that demonstrate high maturity in adopting, standardizing, and scaling their multi-cloud adoption. This year’s survey, commissioned by HashiCorp and once again performed by Forrester Consulting, focuses on operational cloud maturity, defined by the adoption of a combination of technological and organizational best practices at scale. Results highlighted that high-maturity organizations benefit most in the areas of security, governance,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.